OptiNose — Investor Presentation (July 2018)
19 slides from OptiNose's investor presentation, Jul 11, 2018
Slide 1: Building a Leading ENT / Allergy Specialty Company
Exhibit 99.1 Building a Leading ENT / Allergy Specialty Company Corporate Presentation July 12, 2018
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward-looking statements for this pu
Slide 3: Emerging Growth Company with Approved Products
Emerging Growth Company with Approved Products BUILDING A LEADING ENT / ALLERGY SPECIALTY COMPANY XHANCE Represents a Significant Opportunity in Attractive ENT/Allergy Market • 3.5 Million CRS patients (1.2M with nasal polyps) being treated by 15,000 physicians • Limited competition anticipated from
Slide 4: Recent Key Accomplishments
Recent Key Accomplishments Retail Launch Aided Awareness April 2, 2018 87% within ENT / Allergy Specialty* Commercial 74% Lives Covered Total Trialists (61% Tier 3 Single Step or better)* Encouraging Submitted CS Physician Adoption trial design to in ENT / Allergy FDA Continued to Build Capabilities
Slide 5: Successful Launches are Driven by Four Key Factors
Our Research on Over 300 Products Suggests Successful Launches are Driven by Four Key Factors Attractive Market…with High Unmet Need Importantly Differentiated Product Awareness / Execution Market Access 5
Slide 6: CRS is an Attractive Market…With High Unmet Need
CRS is an Attractive Market…With High Unmet Need 30 Million High Burden US Adults suffer from CRS • Disease persists for many years and up to 10 million • Significant quality of life impact of them have nasal (comparable to CHF, COPD, Angina) polyps 9.75 Million CRS patients seek physician Recognize
Slide 7: $3.4B Market Opportunity Within Specialty
$3.4B Market Opportunity Within Specialty TOTAL MARKET OPPORTUNITY OF >$9.5B (Nasal Polyps + CS Indications) SPECIALTY MARKET OPPORTUNITY INCREMENTAL PCP OPPORTUNITY KEY DRIVER 30 Million Chronic Rhinosinusitis Sufferers in US PREVALENCE (7 Million Have Had Surgery) OVERALL TREATED PATIENTS 9.75 Mil
Slide 8: Perceived Differentiation of XHANCE on Key Choice Drivers
Perceived Differentiation of XHANCE on Key Choice Drivers Translates into High Intention to Prescribe XHANCE is Perceived as Physician Stated Interest Differentiated on Key to Prescribe* Choice Drivers High Physician Interest in Prescribing is Reported After Presenting Product Profile (With Only Nas
Slide 9: Multi-Channel Integrated Marketing Program Increased Aided Awareness to 87%
Multi-Channel Integrated Marketing Program Increased Aided Awareness to 87% Awareness & Execution 87% . Digital and Non-Personal Awareness campaign 73% implemented 9/17/2017 65% . Clinical Nurse Educators deployed 11/18/2017 . Xhance Xperience program introduced in early March 28% . Approximately 80
Slide 10: XHANCE has Good Early Launch Market Access
XHANCE has Good Early Launch Market Access XHANCE Overall Access: April 2018 • Nationally, we believe 74% of commercial lives are in a plan where XHANCE is covered. 26% • We believe new drugs that launch at approval typically have 74% only 40% of commercial lives covered and 60% of commercial lives
Slide 11: XHANCE National Market Access
XHANCE National Market Access XHANCE Overall • We are focused on creating Access: April 2018 access for patients that minimizes hassle for prescribers and patients. 26% • XHANCE is on formulary for 65% 9% of commercial lives in a Tier 3 65% position requiring a previous trial of an INS or better. •
Slide 12: XHANCE Xperience Program - Initiated in Market on March 5th
XHANCE Xperience Program - Initiated in Market on March 5th XPERIENCE . Innovative launch program, planned for March through June, offering physicians and patients an opportunity to gain initial experience with XHANCE . Designed to facilitate accelerated trial and adoption, and to help address “prac
Slide 13: XHANCE Launch Accelerated by Xperience
XHANCE Launch Accelerated by Xperience (Week ending June 30, 2018) Cumulative Cumulative Units Dispensed Physician Trialists As of June 30, 36% of 2,415 16,000 2,500 called physicians have 14,483 prescribed XHANCE 14,000 2,000 13,439 12,000 1,500 10,000 8,000 1,000 6,000 4,000 500 2,000 1,044 0 0 To
Slide 14: Encouraging Feedback From Xperience Program Survey
Encouraging Feedback From Xperience Program Survey Patient Responses Prior to Month 2 Refill (N=1,470) Patient Satisfaction 89% Experience Symptom 80% Improvement Prefer XHANCE 78% Recommend XHANCE 90% to a Friend Use without Difficulty 95% Note: in the same period that the 1,470 responses were rece
Slide 15: Market Dynamics, Product Characteristics and Execution Provide a Strong Foundation
Market Dynamics, Product Characteristics and Execution to Date Provide a Strong Foundation for a Successful Launch Indicator/Objective Assessment Attractive Market…with High Unmet Need >80% >80% of patients frustrated with lack of symptom Current Patients Dissatisfied with Existing Treatment relief
Slide 16: Financial Review
Financial Review Q1 2018 Revenues and Q2 and Full Year 2018 Average Selling Price (ASP) Perspectives • A large majority of Q1 revenue is • As planned, we expect the Xperience related to inventory shipped in late- program to be the primary source of March to support retail pharmacy demand for XHANCE
Slide 17: Chronic Sinusitis Supplemental Indication (sNDA)
Chronic Sinusitis Supplemental Indication (sNDA) CS study design Selection of CRO First patients submitted to and study expected to FDA, meeting locations enroll in 4Q 2018 requested Chronic Sinusitis trial design expected to include co-primary endpoints: both an objective measure of inflammation an
Slide 18: 2018 Stands to be an Important Year
2018 Stands to be an Important Year Achieve greater than 87% aided awareness in target ENT and allergist audience during retail launch Secure market access for XHANCE ≥65% of patients with commercial insurance plans at retail launch, expanding to 75% by year end Key Objectives Successfully launch XH
Slide 19: Investor Relations
Investor Relations – NASDAQ: OPTN At 31 March 2018: Analyst Coverage1 – $210 million in cash – Long-term debt: $75 million BMO: Gary Nachman June 2018 Offering: – Net proceeds of $60 million in cash Jefferies: David Steinberg – 40.8 million common shares o/s – 8.2 million options & warrants o/s Pipe